Grant Applications Now Open | Due by November 20, 2026

We are dedicated to fostering the next generation of scientific leaders in cellular therapy by accelerating innovation and research to create a future where cancers and intractable diseases are curable.

10,000+ Patients
Treated to Date

Our CAR-T is bringing hope to patients worldwide and counting.

Helping Redefine What is Possible in Cell Therapy

New long-term evidence presented at IMS 2026 adds to our understanding of the treatment journey.

Creating Hope and New Opportunities

Our pipeline of cell therapies includes agents across hematologic and solid tumors. We focus on diseases that are considered intractable and incurable.

Transforming the World of Oncology and Medicine

We are a 3,000+ team driven by our passion for developing cutting-edge cell therapies.

Our news

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Sep 25, 2026

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Sep 15, 2026

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

Sep 10, 2026

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

Aug 11, 2026

Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

Jul 28, 2026

Legend Biotech Announces CEO Transition

Jul 27, 2026

Why we do what we do

We focus on serious and intractable diseases to help patients around the world.

PLAY VIDEO

Learn about us

Explore our technologies

We are technology agnostic in targeting hematologic malignancies and solid tumors. We are exploring 4 different technologies to help treat disease.

Meet our leadership team

Our leaders bring significant expertise from some of the world’s largest pharma companies.

Understand our capabilities

We are an end-to-end cell therapy company. Our capabilities extend from discovery to commercialization.

Work with us

We offer a variety of career choices that support the development of novel therapies.

Our pipeline

Our pipeline is comprised of investigational agents and innovative technologies in personalized medicine. We are devoted to exploring the potential of cell therapies to treat diseases that are considered intractable and incurable, including hematological malignancies and solid tumors.

LEARN MORE

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.